Watson enters exclusive agreement with OMJPI to market authorized generic Concerta

Links shared publicly online about this topic.

757
total visits

Watson enters exclusive agreement with OMJPI to market authorized generic Concerta

Watson Pharmaceuticals, Inc. today announced that its subsidiary, Watson Laboratories, Inc., has entered into an exclusive agreement with Ortho-McNeil-Janssen Pharmaceuticals, Inc. (OMJPI), to market the authorized generic version of Concerta® (methylphenidate hydrochloride extended-release tablets). Watson will launch its authorized generic of Concerta on May 1, 2011. Concerta is indicated for the treatment of attention deficit hyperactivity disorder (ADHD).

View full resource at news-medical.net

Tags: ADHD Medication, Pharma, Concerta, Metadate CD, Metadate ER, Methylin, Ritalin, Watson Pharmaceuticals